Language:

Assessing the cost-effectiveness of pharmacogenomics

AAPS PharmSci, 2000, Vol.2 (3), p.E29-90 [Peer Reviewed Journal]

American Association of Pharmaceutical Scientists 2000 ;ISSN: 1522-1059 ;ISSN: 1550-7416 ;EISSN: 1522-1059 ;EISSN: 1550-7416 ;DOI: 10.1208/ps020329 ;PMID: 11741245

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Assessing the cost-effectiveness of pharmacogenomics
Author: Veenstra, D L ; Higashi, M K ; Phillips, K A
Subjects: Anticholesteremic Agents - therapeutic use ; Anticoagulants - pharmacokinetics ; Anticoagulants - therapeutic use ; Antimetabolites, Antineoplastic - therapeutic use ; Cardiovascular Diseases - drug therapy ; Cardiovascular Diseases - economics ; Cardiovascular Diseases - enzymology ; Carrier Proteins - genetics ; Child ; Cholesterol Ester Transfer Proteins ; Cost-Benefit Analysis ; Drug Therapy - economics ; Genotype ; Glycoproteins ; Hepatitis C - drug therapy ; Hepatitis C - economics ; Humans ; Interferons - therapeutic use ; Mercaptopurine - therapeutic use ; Methyltransferases - deficiency ; Pharmacogenetics - economics ; Pharmacology, Clinical - economics ; Pharmacology, Clinical - methods ; Phenotype ; Pravastatin - therapeutic use ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - economics ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - enzymology ; Ribavirin - therapeutic use ; Warfarin - pharmacokinetics ; Warfarin - therapeutic use
Is Part Of: AAPS PharmSci, 2000, Vol.2 (3), p.E29-90
Description: The use of pharmacogenomics to individualize drug therapy offers the potential to improve drug effectiveness, reduce adverse side effects, and provide cost-effective pharmaceutical care. However, the combinations of disease, drug, and genetic test characteristics that will provide clinically useful and economically feasible therapeutic interventions have not been clearly elucidated. The purpose of this paper was to develop a framework for evaluating the potential cost-effectiveness of pharmacogenomic strategies that will help scientists better understand the strategic implications of their research, assist in the design of clinical trials, and provide a guide for health care providers making reimbursement decisions. We reviewed concepts of cost-effectiveness analysis and pharmacogenomics and identified 5 primary characteristics that will enhance the cost-effectiveness of pharmacogenomics: 1) there are severe clinical or economic consequence that are avoided through the use of pharmacogenomics, 2) monitoring drug response using current methods is difficult, 3) a well-established association between genotype and clinical phenotype exists, 4) there is a rapid and relatively inexpensive genetic test, and 5) the variant gene is relatively common. We used this framework to evaluate several examples of pharmacogenomics. We found that pharmacogenomics offers great potential to improve patients' health in a cost-effective manner. However, pharmacogenomics will not be applied to all currently marketed drugs, and careful evaluations are needed on a case-by-case basis before investing resources in research and development of pharmacogenomic-based therapeutics and making reimbursement decisions.
Publisher: United States: Springer-Verlag
Language: English
Identifier: ISSN: 1522-1059
ISSN: 1550-7416
EISSN: 1522-1059
EISSN: 1550-7416
DOI: 10.1208/ps020329
PMID: 11741245
Source: Open Access: PubMed Central
MEDLINE
Alma/SFX Local Collection

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Assessing the cost-effectiveness of pharmacogenomics

American Association of Pharmaceutical Scientists 2000 ;ISSN: 1522-1059 ;ISSN: 1550-7416 ;EISSN: 1522-1059 ;EISSN: 1550-7416 ;DOI: 10.1208/ps020329 ;PMID: 11741245

Searching Remote Databases, Please Wait